{
    "nct_id": "NCT05167409",
    "official_title": "A Phase II Study (With Safety run-in) of Evorpacept (ALX148) in Combination With Cetuximab and Pembrolizumab in Patients With Refractory Microsatellite Stable Metastatic Colorectal Cancer",
    "inclusion_criteria": "To be eligible to participate in this study, an individual must meet all of the following criteria:\n\n* Have a diagnosis of metastatic colorectal cancer previously treated with at least two lines of therapy for unresectable/metastatic disease\n* Have microsatellite stable disease\n* Adequate hematologic and end organ function\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "An individual who meets any of the following criteria will be excluded from participation in this study:\n\n* Patients with known MSI-high status or known mismatch repair deficiency (dMMR)\n* Patients in whom both mismatch repair and microsatellite stability status are unknown\n* History of severe allergic, anaphylactic, or other hypersensitivity reactions to any of the study medications or their classes\n* Left-sided (at or distal to the splenic flexure) RAS/BRAF wild-type metastatic colorectal cancer who are EGFR inhibitor naïve.\n* Prior therapy with an anti-PD-1, anti-PD-L1, anti PD L2, anti-CD47, or anti-SIRPα agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX 40, CD137)",
    "miscellaneous_criteria": ""
}